ConductScience.org, home

Paper40356972

Post-marketing safety concerns with pirfenidone and nintedanib: an analysis of individual case safety reports from the FDA adverse event reporting system database and the Japanese adverse drug event report databases.

Wang T and 7 others. Front Pharmacol, 2025. Cited by 10 papers, by iCite.

Cite this record

ConductScience Library. Post-marketing safety concerns with pirfenidone and nintedanib: an analysis of individual case safety reports from the FDA adverse event reporting system database and the Japanese adverse drug event report databases. Papers, record 40356972. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40356972

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Post-marketing safety concerns with pirfenidone and nintedanib: an analysis of individual case safety reports from the FDA adverse event reporting system database and the Japanese adverse drug event report databases.
PubMed
Journal
Front Pharmacol
PubMed
Year
2025
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
10
iCite
Relative citation ratio, by iCite
3.15, provisional
iCite
Revised in PubMed
2025-05-14
PubMed

Authors8

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Wang TTao
2Cui ZZhiwei
3Ou YYingyong
4Lou SSiyu
5Chen HHuayou
6Zhu CChengyu
7Zhou LLinmei
8Zou FFan

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References122

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
133994347Safety and tolerability of combination therapy with pirfenidone and nintedanib for idiopathic pulmonary fibrosis: A multicenter retrospective observational study in Japan.Respir Investig2021https://conductscience.org/library/papers/33994347PubMed
230364407Long-term safety of pirfenidone: results of the prospective, observational PASSPORT study.ERJ Open Res2018https://conductscience.org/library/papers/30364407PubMed
337709326Strategies and interventions to strengthen pharmacovigilance systems in low-income and middle-income countries: a scoping review.BMJ Open2023https://conductscience.org/library/papers/37709326PubMed
428921394Combination Therapy with Pirfenidone plus Prednisolone Ameliorates Paraquat-Induced Pulmonary Fibrosis.Inflammation2018https://conductscience.org/library/papers/28921394PubMed
524836849Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis.Respirology2014https://conductscience.org/library/papers/24836849PubMed
632297284Safety and Efficacy of Pirfenidone in Advanced Idiopathic Pulmonary Fibrosis: A Nationwide Post-Marketing Surveillance Study in Korean Patients.Adv Ther2020https://conductscience.org/library/papers/32297284PubMed
736585256Inhibition of MRTF activation as a clinically achievable anti-fibrotic mechanism for pirfenidone.Eur Respir J2023https://conductscience.org/library/papers/36585256PubMed
825651859Delays in the post-marketing withdrawal of drugs to which deaths have been attributed: a systematic investigation and analysis.BMC Med2015https://conductscience.org/library/papers/25651859PubMed
928091615Pirfenidone controls the feedback loop of the AT1R/p38 MAPK/renin-angiotensin system axis by regulating liver X receptor-α in myocardial infarction-induced cardiac fibrosis.Sci Rep2017https://conductscience.org/library/papers/28091615PubMed
1039821007Real-world safety of maribavir: a retrospective study based on signal detection in the FDA adverse event reporting system.Int J Clin Pharm2025https://conductscience.org/library/papers/39821007PubMed
1128883482Low body surface area predicts hepatotoxicity of nintedanib in patients with idiopathic pulmonary fibrosis.Sci Rep2017https://conductscience.org/library/papers/28883482PubMed
1228232409Baseline characteristics of idiopathic pulmonary fibrosis: analysis from the Australian Idiopathic Pulmonary Fibrosis Registry.Eur Respir J2017https://conductscience.org/library/papers/28232409PubMed
1332664913Expert consensus on the management of adverse events and prescribing practices associated with the treatment of patients taking pirfenidone for idiopathic pulmonary fibrosis: a Delphi consensus study.BMC Pulm Med2020https://conductscience.org/library/papers/32664913PubMed
1438434706Adverse drug events associated with linezolid administration: a real-world pharmacovigilance study from 2004 to 2023 using the FAERS database.Front Pharmacol2024https://conductscience.org/library/papers/38434706PubMed
1531016670Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib.Clin Pharmacokinet2019https://conductscience.org/library/papers/31016670PubMed
1638044938Risk factors for drug-related acute pancreatitis: an analysis of the FDA adverse event reporting system (FAERS).Front Pharmacol2023https://conductscience.org/library/papers/38044938PubMed
1729101500Early clinical experiences with nintedanib in three UK tertiary interstitial lung disease centres.Clin Transl Med2017https://conductscience.org/library/papers/29101500PubMed
1818690886The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway.Curr Clin Pharmacol2008https://conductscience.org/library/papers/18690886PubMed
1927005406Pirfenidone-induced severe phototoxic reaction in a patient with idiopathic lung fibrosis.J Eur Acad Dermatol Venereol2016https://conductscience.org/library/papers/27005406PubMed
2024836312A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.N Engl J Med2014https://conductscience.org/library/papers/24836312PubMed

See all 122 referencesDownload CSV of references

Cited by7

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 10 citations.

PMIDTitleJournalYearIn PapersSource
42781927TRPML1 agonist ML-SA5 attenuates pulmonary fibroblast activation by suppressing mTOR and restoring autophagic flux.FEBS Open Bio2026https://conductscience.org/library/papers/42781927PubMed
42369125Comparative efficacy of different types of structured exercise interventions for idiopathic pulmonary fibrosis: a systematic review and meta-analysis.Front Med (Lausanne)2026https://conductscience.org/library/papers/42369125PubMed
41995999Efficacy and tolerability of generic pirfenidone after switch from Esbriet® in idiopathic pulmonary fibrosis: a real-world observational study.Intern Emerg Med2026https://conductscience.org/library/papers/41995999PubMed
41891405Combination antifibrotic and immunosuppressive therapy in progressive fibrosing ILD.Sarcoidosis Vasc Diffuse Lung Dis2026https://conductscience.org/library/papers/41891405PubMed
41522097Adverse side-effects of antifibrotic drugs and outcome of treatment in idiopathic pulmonary fibrosis.J Thorac Dis2025https://conductscience.org/library/papers/41522097PubMed
41507413​​Rubiadin-1-methyl ether alleviates bleomycin induced pulmonary fibrosis​.Sci Rep2026https://conductscience.org/library/papers/41507413PubMed
41132892Refractory Spontaneous Pneumothorax in Interstitial Lung Disease Under Pirfenidone Treatment.Respirol Case Rep2025https://conductscience.org/library/papers/41132892PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/40356972

GET https://conductscience.org/api/papers/v1/40356972/references?page=2